Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions,gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients’ symptoms disappeared.
Abstract
Bortezomib is an inhibitor of 26S proteasome, which is an effective treatment for multiple myeloma. The common adverse effects of bortezomib are asthenic conditions,gastrointestinal disturbances, and peripheral neuropathy. Here we describe a patient with dyspnea and general weakness because of complete atrioventricular block while receiving bortezomib. We immediately stopped bortezomib, and after inserting a permanent VDD pacemaker, the patients’ symptoms disappeared.
참고문헌 (6)
- Dasanu CA, "Complete heart block secondary to bortezomib use in multiple myeloma", J Oncol Pharm Pract (2010)
- Colson K, "Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications", Clin J Oncol Nurs, 8, pp.473~480 (2004)
- Cavaletti G, "Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat", Exp Neurol, 204, pp.317~325 (2007)
- Shah MH, "Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors", Clin Cancer Res, 10, pp.6111~6118 (2004)
- Berenson JR, "Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma", Cancer, 104, pp.2141~2148 (2005)
- Reece DE, "Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study", Blood, 114, pp.1489~1497 (2009)